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Abstract
Introduction Sarcopenia is defined by a loss of muscle mass and function associated with mortality, decreased physical 
performance, falls, and disability. Since chronic inflammation and decreased physical activity are risk factors for developing 
sarcopenia, it is critical to assess the role of sarcopenia in immune-mediated rheumatic diseases (IMRDs). Moreover, nutri-
tional interventions are emerging as key modifiable and affordable options to improve physical performance in sarcopenia.
Objective The aim of this review is to critically summarize current information on the evidence linking nutritional interven-
tions and sarcopenia in IMRDs.
Methods The search and selection of articles was performed in Medline, Dimensions.ai, Google Scholar, Cochrane Library, 
Epistemonikos, and Trip Database. The results were clustered into three areas: sarcopenia and IMRDs, sarcopenia and bio-
logical disease-modifying antirheumatic drugs (bDMARDs), and nutritional interventions for sarcopenia.
Findings Several cross-sectional studies have shown a higher prevalence of sarcopenia in IMRDs, such as rheumatoid 
arthritis. Although not fully established, evidence linking sarcopenia and other IMRDs (ankylosing spondylitis and systemic 
sclerosis) has been also described. For secondary sarcopenia prevention and treatment, bDMARDs’ administration proved 
efficacy in patients with rheumatoid arthritis. Furthermore, there is growing evidence linking nutrition to the prevention and 
treatment of sarcopenia. Evidence linking unfavourable results in nutritional risk assessment, insufficient intake of protein, 
vitamin D, antioxidant nutrients, and long-chain polyunsaturated fatty acids and sarcopenia have been reported.
Conclusion Given that sarcopenia and IMRDs have strong links, further research is needed to improve patient care.
Keywords Sarcopenia · Immune-mediated rheumatic diseases · IMRDs · Inflammation · Rheumatoid arthritis · Biological 
disease-modifying antirheumatic drugs · bDMARDs · Nutritional interventions
Introduction
Sarcopenia is a generalized musculoskeletal disorder char-
acterized by loss of muscle mass and function together with 
decreased physical performance. Loss of muscle mass and 
function leads to a higher risk of falls and hospitalization 
rates, decreases the ability to perform activities of daily liv-
ing, increases functional impairment, worsens quality of life, 
and increases morbidity [1–3].
Sarcopenia is highly prevalent in older patients and is 
an important factor contributing to frailty and disability, 
generating a significant social and economic burden [4]. 
Sarcopenia prevalence in the community is highly variable 
(3–24%) as a result of the range of diagnostic criteria and 
definitions used [5].
Apart from age, sarcopenia-related risk factors include 
nutritional deficiencies, sedentarism, decreased protein syn-
thesis and regeneration, inflammation, and hormonal and 
cytokine imbalance, among others [6, 7].
The definition, diagnosis, and assessment of sarcopenia 
is well described in the literature. The EWGSOP (European 
Working Group on Sarcopenia Older People) definition 
of sarcopenia put muscle strength to the forefront, as it is 
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recognised that strength is better than mass in predicting 
adverse outcomes. In addition, it recommends an algorithm 
for case finding, diagnosis, and determination of the severity 
of sarcopenia [2, 3, 8, 9].
Methods
The literature search for this scoping review was conducted 
in the following databases since 2014 and in English: Med-
line, Dimensions.ai, Google Scholar, and Cochrane Library 
and the evidence-based medicine repositories: Epistemon-
ikos and Trip Database, with the search completion date 
11/29/2019. Search strings were performed on the above 
databases constructed from the term nutritional interven-
tions and/or immune-mediated rheumatic diseases and/or 
sarcopenia and all their equivalents or synonyms as input 
terms into the MeSH (Medical Subject Headings) database, 
the NLM (National Library of Medicine) controlled vocabu-
lary thesaurus. For screening, a restriction was made to those 
papers included older adults with sarcopenia and diagnosis 
immune-mediated rheumatic diseases (specifically rheuma-
toid arthritis, ankylosing spondylitis, and systemic sclero-
sis). A secondary manual literature search of the selected 
studies was also conducted to detect possible omissions 
that could be of interest. Articles were selected in pairs and 
reviewed in full text to give a detailed view of this complex 
field. The results were clustered into three areas: sarcopenia 
and immune-mediated rheumatic diseases (IMRDs); sarco-
penia, immune-mediated rheumatic diseases and biological 
disease-modifying antirheumatic drugs (bDMARDs); and 
nutritional interventions for sarcopenia.
Sarcopenia and immuno‑mediated 
rheumatic diseases
IMRDs are accompanied by inflammation, especially joint 
inflammation, causing pain, joint dysfunction, and destruc-
tion, decreased physical activity and quality-of-life impair-
ment. Since decreased physical activity and chronic inflam-
mation are risk factors for sarcopenia, it seems relevant to 
assess the prevalence of sarcopenia and its association with 
inflammatory markers, and rheumatic disease course and 
activity, among others, in patients with IMRDs.
Inflammatory markers in sarcopenia
Chronic inflammation is a risk factor for developing sar-
copenia, because it facilitates muscle catabolism [10]. It is 
not clear which serum inflammatory molecules are associ-
ated with loss of muscle mass and strength and physical 
performance and which, as such, may be candidates for sar-
copenia biomarkers [11].
A cross-sectional study exploring neuromuscular, periph-
eral pro‐inflammatory, and oxidative stress molecules as 
potential biomarkers associated with sarcopenia in old-aged 
people with hip fracture only found differences in peripheral 
TNF‐α levels and catalase activity. Probably, TNF‐α and 
catalase are markers of an early inflammatory reaction that 
is impaired in subjects with sarcopenia [12].
A randomized-controlled trial (RCT) published in 2019 
evaluated the association between body composition and 
inflammatory markers in 1,121 healthy individuals between 
65 and 79 years old. It found that muscle mass [assessed 
by skeletal muscle mass index (SMI): appendicular skeletal 
muscle mass (ASMM)/height2] negatively correlates with 
proinflammatory serum levels of C-reactive protein (CRP), 
leptin, and alpha-1-acid glycoprotein (AGP), and positively 
correlates with Ghrelin, in both men and women [13].
High levels of CRP have also been observed in sarcope-
nia patients in several cross-sectional studies. A systematic 
review and meta-analysis conducted in 2016 observed a 
correlation between significantly higher levels of CRP and 
sarcopenia (defined as muscle mass loss) [11]. In a cross-
sectional study, Can et al. [14] showed that patients with 
sarcopenia (defined by EWGSOP criteria) had higher levels 
of CRP and adiponectin and a higher erythrocyte sedimen-
tation rate (ESR). ESR was independently associated with 
sarcopenia (OR = 1.156; 95% CI 1.057–1.263; p = 0.001). In 
another cross-sectional study, van Atteveld et al. [15] also 
determined significant inverse correlations between ESR and 
muscle mass [relative skeletal muscle mass (RMM): skeletal 
muscle mass (SMM)/weight], muscle strength (grip strength 
and chair stand test), and physical performance [normal 
walking speed and timed up and go (TUG)]. Moreover, they 
observed an association between lower albumin levels and 
lower muscle strength and physical performance. Otzurk 
et al. [16] performed a cross-sectional study and observed 
higher ESR and higher CRP levels in patients with sarcope-
nia (defined by EWGSOP criteria) than in controls. These 
authors also analysed the neutrophil/lymphocyte ratio (NLR) 
and observed an independent association between NLR and 
sarcopenia (OR = 1.31, 95% CI 1.06–1.62, p = 0.013).
A cross-sectional study included a multivariate analysis 
of 30 serum inflammatory markers in patients with sarcope-
nia and frailty, and observed a specific pattern of inflamma-
tory markers, with higher levels of CRP, and lower levels of 
IL-8, myeloperoxidase (MPO), monocyte chemoattractant 
protein 1 (MCP1), and platelet-derived growth factor BB 
(PDGF-BB). This study also showed gender-specific pat-
tern differences: for example, women had higher levels of 
selectin P and eotaxin, while men had lower levels of IFN-γ, 
IL-17, and TNF-α, among others [17].
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Finally, CRP and IL-8 levels and adiponectin/leptin ratio 
may have prognostic value for the development of sarco-
penia. A longitudinal study that included 336 adults aged 
59–70 years of age, with an average follow-up period of 
10.8 years, observed significant associations between higher 
levels of CRP, higher levels of IL-8, and a lower adiponec-
tin/leptin ratio at baseline and the development of sarcopenia 
(defined by EGWSOP) at the follow-up visit [18].
Sarcopenia and rheumatoid arthritis
Loss of muscle strength in patients with RA may be seen 
frequently. Longer disease duration and higher disease activ-
ity should lead to development of sarcopenia due to chronic 
inflammation [19].
Several cross-sectional studies have shown a higher prev-
alence of sarcopenia in patients with rheumatoid arthritis 
(RA) compared to healthy controls [20–25]. The prevalence 
of sarcopenia described in studies in patients with RA ranges 
from 7.8% [26] to 87.5% [24]. One of the reasons for these 
differences is the different criteria and assessment methods 
for sarcopenia used in each study. Even so, it should be noted 
that in a cross-sectional study by Tournadre et al. [26] found 
the same sarcopenia prevalence in RA patients (low, 7.8%) 
using both the EWGSOP definition (muscle mass and func-
tion) and muscle mass alone (SMI: ASMM/height2).
Several studies have analysed factors associated with the 
development of sarcopenia in patients with RA. Although 
not fully established, these include, but are not limited to, 
age, sex, nutritional status, disease activity, and degree of 
disability.
Gender
Several studies have shown gender differences in the preva-
lence of sarcopenia in RA patients [23, 27]. In a cross-sec-
tional study, Baker et al. [27] found that muscle mass [meas-
ured with appendicular lean mass index (ALMI): ALM/
height2] was lower in men than in women (p < 0.0001) and 
they observed a 3–8 times higher probability of sarcopenia 
in men in one of the two study cohorts. Male sex was also 
associated with the development of sarcopenia in the cor-
relation research of sarcopenia, skeletal muscle, and disease 
activity in RA [28].
Nutritional status
Although body mass index (BMI) has been associated with 
sarcopenia in previous publications [28–32], many studies 
show that muscle mass loss is not always associated with 
lower BMI. The low or no weight loss in these patients is 
explained by a stable or slightly increased fat mass, i.e., sar-
copenic obesity. The concept of sarcopenic obesity is still 
an evolving one and has not been well studied in rheumatic 
diseases [33]. One observational study evaluated sarcopenia 
(defined by SMI) in women with RA vs. healthy controls and 
concluded that despite having a similar BMI, the prevalence 
of sarcopenia was significantly higher in patients with RA 
[20]. Accordingly, one transversal study in men and women 
with RA correlated sarcopenia (defined by SMI) to normal 
BMI (OR = 82.1, 95% CI 3.8–1733.3; p = 0.005) and over 
fat BMI (OR = 12.3; 95% CI 2.27–67.6; p = 0.004) [21]. A 
cross-sectional study by Vlietstra et al. [34] observed an 
association between sarcopenia (defined according to mus-
cle mass) and higher fat content (OR = 1.1, 95% CI 1.0–1.2; 
p < 0.02), and use of glucocorticoids (OR = 1.08; 95% CI 
1.0–1.2; p = 0.017) in patients with RA.
Disease activity
The relationship between the presence of sarcopenia and RA 
activity or severity is not clearly established. Some studies 
have found no association between sarcopenia and mark-
ers of disease activity such as Disease Activity Score 28 
(DAS28) [20, 21, 32, 35]. In a cross-sectional study, Bar-
one et al. [35] observed a prevalence of sarcopenia (muscle 
mass and strength) of about 20% in patients with RA, but 
no relationship with RA activity. In contrast, disability and 
age were positively associated in this study with sarcopenia.
Other studies in RA have positively correlated disease 
duration and activity with sarcopenia. In a longitudinal study 
of 294 RA patients, Park et al. [36] showed that sarcopenia 
(defined by SMI) has a prognostic value for increased dis-
ease activity (DAS28-ESR) at 3 years (OR = 4.477; 95% CI 
1.661–12.067; p = 0.003). Another cross-sectional study in 
women with RA observed an association between inflam-
mation levels and long-standing RA (CRP levels) and mus-
cle mass (ALMI) [37]. In a case–control study, Reina et al. 
[30] found that BMI, SMI, and lean appendicular mass are 
inversely correlated, and that fat mass is directly correlated 
with disease duration in patients with RA, in both men 
and women. A cross-sectional study of 388 women with 
RA observed that disease duration (OR = 1.06; 95% CI 
1.04–1.09), joint damage (Steinbrocker’s class, OR = 3.19, 
95% CI 1.60–6.53), and age (OR = 1.64; 95% CI 1.26–2.17) 
were independent factors positively associated with sarcope-
nia [defined by muscle mass, strength, and function, accord-
ing to the Asian Working Group on Sarcopenia (AWGS) 
definition]. However, bDMARDs use (OR = 0.51; 95% CI 
0.28–0.93) and a good nutritional status (OR = 0.61; 95% CI 
0.51–0.71) were negatively associated with sarcopenia [31].
Other studies have also observed an association between 
sarcopenia (defined by muscle mass, SMI) and radiographic 
joint damage (OR = 2.154; 95% CI 1.032–4.497; p = 0.041) 
[38] and bone erosion (OR = 0.057; 95% CI 0.006–0.532; 
p = 0.012) in patients with RA [21].
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Disability and falls
A cross-sectional study of 240 patients with RA showed 
no significant relationship between a disability index or 
RA activity (determined by DAS28-ESR) and sarcopenia 
(defined by AWGS). Factors associated with sarcopenia in 
this study were age (OR = 1.08, p = 0.008), BMI (OR = 0.73, 
p < 0.001), CRP (OR = 1.76, p = 0.017), and hip bone min-
eral density (BMD) (OR = 0.61, p = 0.037) [32].
CHIKARA is a prospective, observational study that 
included 100 patients of both sexes with RA. Early analy-
sis showed an independent correlation between sarcopenia 
(defined by the AWGS definition) and high body fat mass, 
low BMI, and high matrix metalloproteinase-3 (MMP3) 
[29]. In a subsequent study, univariate analysis observed 
that male sex, old age, glucocorticoid use > 5 mg/day, high 
levels of MMP3, and higher disability evaluated by the 
Health Assessment Questionnaire (HAQ) were associated 
with sarcopenia (defined by AWGS) development at 2 years 
in RA patients [28].
Sarcopenia is a risk factor for fall events. In a cross-sec-
tional study, Vlietstra et al. [34] showed a weak association 
between sarcopenia (defined by muscle mass) and fatigue in 
patients with RA. Nevertheless, the analysis of CHIKARA 
data at 1 year did not show a significant relationship between 
the risk of fall events and sarcopenia (defined by AWGS). 
No relationship was observed between the risk of fall events 
and disease activity and CRP; but height and obesity levels 
showed a negative correlation with fall events [39].
Bone mineral density
Decreased muscle mass may appear together with decreased 
bone mass, in what has been named osteosarcopenia [40, 
41], but the relationship of sarcopenia, low BMD, and osteo-
porosis in RA patients is not fully established understood 
[42].
Confavreux et al. [43] revised the systemic bone effects 
of biologic therapies in IMRDs (such as RA and ankylos-
ing spondylitis). Feklistov et al. [22] observed osteoporo-
sis (low BMD) in a cross-sectional study among 48% of 
women with RA versus 45% in healthy controls. Sarcope-
nia (muscle mass, strength, and physical performance) was 
observed in 25% of RA patients, and osteosarcopenia (sar-
copenia + low BMD) was found in 15%, versus 12.5% and 
5% in healthy controls, respectively. TOMORROW study 
was a prospective cohort that shows data from 208 patients 
with RA and 205 age- and sex-matched healthy controls 
[44, 45]. Okano et al. [44] showed lower muscle mass and 
lower BMD in patients with RA, and a positive correlation 
between both parameters. In a subsequent subanalysis of 
this cohort, Inui et al. analysed muscle mass and BMD in 
individuals > 65 years for a period of 7 years, and observed 
that muscle mass [determined by appendicular skeletal mass 
index (ASMI)] is an independent factor associated with 
BMD change (p = 0.0020) in patients with RA but not in 
healthy controls [45].
Frailty
Sarcopenia and frailty, defined as physical and cognitive 
function deterioration in older adults, often overlap [46]. 
Early detection of frailty and its risk factors, such as sar-
copenia, is important for prevention and management. In a 
cross-sectional study of 282 patients with AR, prevalence 
of frailty was as high as 21.5%, and 42% of them were 
older than 65 years. Overall, 31% of patients had sarcope-
nia (defined by SMI) [47]. In a cross-sectional analysis of 
CHIKARA study data at 1 year, Tada et al. [48] observed a 
positive association between sarcopenia (defined by AWGS) 
and frailty (OR = 3.1; 95% CI 1.2–1.8; p < 0.024). Observed 
frailty and pre-frailty prevalences were 18.9% and 38.9%, 
respectively. In these groups, sarcopenia prevalence was 
39% and 41%, respectively, and among patients without 
frailty, it was 18%. Other risk factors were MMP3 levels, 
age, disease severity, and joint dysfunction, whilst RA treat-
ment was associated negatively with the onset of sarcopenia. 
Finally, a cross-sectional study of 210 patients with RA and 
100 healthy controls found a higher prevalence of frailty 
among RA patients, showing 16.6% with frailty and 32.4% 
with pre-frailty. Risk factors associated with frailty were 
age (OR = 1.12; 95% CI 1.07–1.17; p < 0.0001), comorbidi-
ties (OR = 1.51; 95% CI 1.01–2.27; p = 0.0446), and disease 
activity (OR = 1.10; 95% CI 1.04–1.16; p = 0.0006) [49].
Sarcopenia and ankylosing spondylitis
Ankylosing spondylitis (AS) causes decreased bone mass, 
stiffness, and movement loss, which may be related to loss of 
muscle mass and the development of sarcopenia. However, 
the prevalence and impact of sarcopenia in AS patients has 
not yet been clearly established [35, 50].
A cross-sectional by Ibáñez et al. [51] observed a decrease 
in muscle mass (and fat mass) associated with disease activ-
ity in male patients with AS, but not in women with AS. In 
both men and women, disease activity [Ankylosing Spon-
dylitis Disease Activity Score (ASDAS) CRP] correlated 
negatively with fat mass. In a cross-sectional study of 10 
patients with AS and 10 healthy controls, Røren et al. [52] 
observed significantly lower appendicular lean body mass 
(but no total mass), lower muscle strength, and a reduced 
number of type II muscle fibres in patients with AS.
A cross-sectional carried out by El Maghraoui et al. [53], 
which included 67 males with AS and 67 healthy controls, 
observed lower muscle mass in patients with AS. Preva-
lences of pre-sarcopenia, sarcopenia (defined by EWGSOP), 
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and cachexia in patients with AS were 50.4%, 34.3%, and 
11.9%, respectively. Sarcopenia and cachexia were signifi-
cant associated with higher disease activity (Bath Anky-
losing Spondylitis Disease Activity Index [BASDAI]) and 
lower BMD. Finally, in a cross-sectional study by Barone 
et al. [35] also observed a high prevalence of sarcopenia 
among patients with AS, around 20%.
Sarcopenia and systemic sclerosis
Several studies have observed a high prevalence of sarcope-
nia among patients with systemic sclerosis (SS), higher than 
that of healthy individuals [35, 54–57].
In a large cohort of 141 patients with SS, the prevalence 
of sarcopenia (defined by SMI) was around 20.7%. Impor-
tantly, sarcopenia prevalence in malnourished patients was 
significantly higher [54]. In a pilot intervention study of 
18 patients with SS and gastrointestinal involvement, the 
percentage of patients with sarcopenia (defined by mus-
cle mass) was lower after 6-week nutritional intervention 
(54–39%, p < 0.02) [55].
However, the association between sarcopenia and disease 
duration in patients with SS has not been established [54, 
56, 57].
These studies show an interesting relationship between 
IMRDs and sarcopenia, but are burdened by differences in 
sarcopenia-related terms definitions, especially those that 
only evaluate muscle mass, and those that use a modern 
definition of sarcopenia.
Sarcopenia, immune‑mediated rheumatic 
diseases, and biological disease‑modifying 
antirheumatic drugs
Treatment of IMRDs may have an impact on sarcopenia. 
However, only a few studies have reported on the links 
between drugs and sarcopenia in this setting.
The deleterious effects of glucocorticoid (GC) on mus-
cles have been well described elsewhere [58]. Patients with 
IMRDs using GC are at high risk for fractures, due to both 
the direct and indirect negative effects of GC on bone mass, 
and bone and muscle strength, and due to activity of the 
underlying inflammatory disease [59]. In a cross-sectional 
analysis of CHIKARA in patients with RA, GC use was 
more frequent among patients with sarcopenia than in 
patients without sarcopenia. Univariate analysis showed that 
GC dose was significantly associated with sarcopenia onset 
[60]. However, few data are available on other drugs used 
to treat IMRDs.
A prospective cohort study by Hasegawa et al. [61] evalu-
ated bDMARDs’ activity on sarcopenia in men and women 
with RA starting bDMARDs treatment for the first time. 
bDMARDs used in the study included certolizumab pegol 
(24.4%), adalimumab (17.1%), abatacept (17.1%), goli-
mumab (14.6%), tocilizumab (12.2%), infliximab (7.3%), 
and etanercept (7.3%). After 6 months of treatment with 
bDMARDs, physical activity, nutritional status, and qual-
ity of life significantly improved, and disease activity also 
was significantly reduced. Although muscle mass did not 
increase notably, the proportion of patients with sarcope-
nia tended to decrease. In view of these data, the authors 
suggested that bDMARD administration may be useful for 
secondary sarcopenia prevention in patients with RA. Simi-
larly, in a cross-sectional study by Torii et al. [31] observed a 
negative association between bDMARDs use and sarcopenia 
in women with RA.
Briot et al. [62] in a prospective open study analysed the 
effect of anti-TNF-α treatment in male and female patients 
with spondyloarthropathy. Drugs used in this study included 
infliximab (89.5%) and etanercept (10.5%). After 1 year of 
treatment, significant increases in body weight, BMD, bone 
markers, and IGF-1 were observed. Therefore, treatment 
with anti-TNF-α in AS improves bone resorption together 
with an increase in body weight, lean body mass, and IGF-1.
These limited data regarding bDMARDs therapy suggest 
that this treatment has the potential to improve sarcopenia. 
Hence, future studies exploring this outcome are of the out-
most interest.
Nutritional interventions for sarcopenia
There is growing evidence linking nutrition to muscle mass, 
strength, and function, suggesting its important role in both 
the prevention and treatment of sarcopenia [63]. Appropri-
ate quality dietary patterns that ensure sufficient intake of 
protein, vitamin D, antioxidant nutrients, and long-chain 
polyunsaturated fatty acids are key modifiable and afford-
able interventions to improve physical performance in older 
people and/or in patients with particular diseases, such as 
frailty or sarcopenia [64–66].
A systematic literature review evaluated the association 
between sarcopenia and nutritional status, and observed a 
relationship between sarcopenia and a poor nutritional status 
[67].
In another systematic review evaluated the quality of the 
diet and sarcopenia, studying muscle mass, strength and 
physical performance, and sarcopenia risk. Evidence show-
ing a relationship between “healthier” diets and better results 
in muscle mass and strength was low. In contrast, a relation-
ship between “healthier” diets and a lower risk of decreased 
physical performance and a reduced risk of sarcopenia were 
observed. This study, then, shows benefits associated with 
“high quality” diets for physical performance improvement 
in older patients [68].
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An observational study called SarcoPhAge study assessed 
micronutrient and macronutrient intake in patients of both 
sexes with sarcopenia. Study results suggest an association 
between an unbalanced diet and sarcopenia and poor mus-
culoskeletal health, although further prospective studies are 
needed to confirm these findings [64]. Current guidelines 
on sarcopenia management consider the role of nutritional 
intervention on sarcopenia, but overall evidence is weak 
[69].
Proteins
Dietary proteins provide essential amino acids for muscle 
protein synthesis, and of these, leucine is especially impor-
tant. Moreover, dietary proteins may act as an anabolic 
trigger, playing a key role in muscle protein synthesis [66, 
70]. Protein turnover is key to balancing catabolism and 
anabolism and to maintaining muscle mass balance. Several 
studies show that an adequate high-quality protein intake is 
essential to maintain muscle mass. However, studies linking 
protein/amino acid intake to muscle strength and mass and 
function show inconsistent results [65].
A critical review by Hickson [70] found that trials per-
formed with complete protein supplementation did not show 
a consistent effect on muscle mass, strength, or function. 
This could be explained by differences in study design, pro-
tein supplement composition and failure to monitor volun-
tary food intake, compliance, and baseline nutritional status. 
However, a systematic review by Shad et al. [71] showed that 
administrating aminoacid/protein to young and old individu-
als induces muscle protein synthesis (MPS). Moreover, the 
amino acid/protein dose and leucine content should exceed a 
certain threshold to stimulate equivalent MPS rates in young 
and older adults. Below this threshold, age-related muscle 
anabolic resistance is observed.
A systematic review and meta-analysis evaluated the 
efficacy of dairy proteins in sarcopenia-related functions in 
middle-aged and older adults. Dairy protein supplementa-
tion significantly increased appendicular muscle mass in 
middle-aged and older adults, although it showed no effect 
on improving muscle strength [72]. Finally, a systematic 
review analysed the effects of leucine or leucine-enriched 
protein (range 1.2–6.0 g leucine/day) supplementation in 
sarcopenic patients. Results showed that leucine adminis-
tration improved sarcopenia by improving lean muscle mass. 
The effect on muscle strength showed mixed results, and the 
effect on physical performance has been little studied [73].
In brief, there is significant evidence of the importance 
of protein intake as the main stimulus for muscle protein 
synthesis and for maintaining muscle mass and strength in 
old age. Several expert groups have proposed an increase 
in dietary protein recommendations for older age groups to 
1.0–1.2 g/kg body weight per day. However, more studies are 
needed to understand the specific benefit of a high-protein 
diet on physical function [66].
Vitamin D
Muscle mass loss and vitamin D deficiency often occur 
concomitantly, and are linked to weakness, fall events, 
and frailty in older patients [66]. Vitamin D receptors are 
widely expressed in muscle cells; however, their expression 
decreases with age, contributing to sarcopenia. Indirectly, 
vitamin D regulates calcium levels in the muscle and muscle 
fibre atrophy. Vitamin D deficiency causes muscle weakness 
that can be reversed with external vitamin D administra-
tion. Several studies associate muscle mass with vitamin D 
levels, although this relationship has not been fully clarified 
[65, 74].
It is difficult to assess the role of vitamin D, because there 
are no studies of vitamin D alone without protein supple-
mentation. An RCT named The PROVIDE study evaluated 
vitamin D and leucine-enriched diets in older adults with 
sarcopenia. After 13 weeks, an improvement in muscle mass 
and lower limb function was observed in sarcopenic patients, 
highlighting the value of nutritional supplementation among 
these patients [75]. In an RCT carried out by Bo et al. [76] 
also showed that combined supplementation with protein, 
vitamin D, and vitamin E can significantly improve muscle 
mass [relative skeletal mass index (RSMI)], muscle strength 
and anabolic markers such as IGF-I and IL-2 in older adults 
with sarcopenia.
In short, we found significant evidence of the benefits of 
vitamin D supplementation, when included in multicom-
ponent oral nutritional supplements, in maintaining muscle 
mass, strength, and physical function in old age, and in pre-
venting and treating sarcopenia [66].
Omega‑3 fatty acids
It has been suggested that the anti-inflammatory proper-
ties of ω-3 fatty acids (ω-3) are beneficial for muscle mass, 
strength, and function, and that they can prevent the low-
grade, age-related chronic inflammation that contributes to 
the development of sarcopenia. Although the mechanisms by 
which ω-3 exert their effect on muscle mass and function are 
still unclear, a growing number of studies demonstrate the 
potential beneficial effect of dietary supplementation with 
ω-3 in older sarcopenic individuals [77]. A review found 
that ω-3 supplementation seems to increase muscle mass and 
prevent muscle catabolism independent of anabolic stimuli 
or anti-inflammatory effects in patients with primary and 
secondary sarcopenia. However, one of the included stud-
ies failed to show any effect of supplementation on muscle 
mass [78].
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β‑Hydroxy‑β‑methylbutyrate
β-Hydroxy-β-methylbutyrate (HMB) has been shown to 
reduce protein degradation, increase protein synthesis, and 
increase cholesterol production in muscle cells, conferring 
more stability to cell membranes. Moreover, HMB is a leu-
cine metabolite, and 5–10% of ingested leucine is converted 
into HMB. HMB administration has shown benefits in mus-
cle mass loss, strength, and function in several studies [70].
In an RCT conducted by Cramer et al. [79] evaluated 
high-protein oral + HMB nutritional supplementation in 
malnourished adult patients. Nutritional supplementation 
improved strength outcomes in malnourished older patients 
with sarcopenia. In patients with mild–moderate sarcopenia, 
nutritional supplementation + HMB improved strength and 
muscle quality in lower limbs compared to controls.
Oktaviana et al. [80] performed a systematic review to 
determine HMB effects on sarcopenic or fragile individuals. 
The results showed increased lean body mass and preserved 
muscle strength and function after HMB supplementation. 
The main limitation was the reduced number of currently 
available studies with HMB. In this respect, the effect of 
HMB supplementation on the mass, strength, and muscle 
function of older people with sarcopenia or frailty may be 
underestimated. A review evaluated the effect of oral HMB-
enriched protein-rich nutritional supplements and found that 
they mitigated the decline of muscle mass and preserved 
muscle function, especially during hospital rehabilitation 
and recovery [81].
Therefore, more randomized clinical studies evaluating 
HMB administration in different clinical settings are needed 
to determine the benefits of supplementation.
Other micronutrients
It has been suggested that the antioxidant elements (vita-
mins C, E, and carotenoids and trace elements: Cu, Mn, Se, 
and Zn) intervene in muscle mass and strength, while min-
erals (Mg) intervene in muscle function and performance, 
and particular biocomponents, such as phenols, in muscle 
strength and mass [65].
The SarcoPhAge study assessed the micronutrient and 
macronutrient intake of patients of both sexes with sarcope-
nia. The adjusted analysis showed that sarcopenic patients 
consumed significantly lower amounts of two macronutri-
ents (protein, lipids) and five micronutrients (potassium, 
magnesium, phosphorus, iron, and vitamin K) compared to 
non-sarcopenic participants (p < 0.005) [64].
Combined nutritional interventions
A systematic review evaluated the effect of nutritional inter-
vention combined with physical activity on muscle mass and 
function in individuals over 60 years of age. Physical activ-
ity affected muscle mass and function positively; however, 
the results of interactive effects with the nutritional inter-
vention were limited [82]. A systematic review evaluated 
the effect of nutritional intervention, physical activity, and 
the combined effect. The results highlight the importance 
of physical exercise (with and without concomitant nutri-
tional interventions) for improving physical performance in 
patients with frailty and sarcopenia. In these patients, mus-
cle strength improved with multidisciplinary treatment and 
physical exercise [83].
Immune‑mediated rheumatic diseases 
and nutritional interventions
Nutritional abnormalities are prevalent in patients with 
IMRDs, and affect prognosis, quality of life, autonomy, inde-
pendence, and even mortality. The aetiology of nutritional 
alterations is multifactorial, and malnutrition can be associ-
ated with chronic inflammatory processes (cachexia), acute 
inflammatory processes (protein-calorie malnutrition), and 
low food intake [84].
Nutrition plays an important role in both the progression 
and clinical outcomes of inflammatory diseases such as RA. 
Although the effect of nutrition on musculoskeletal dis-
eases is not well studied, several clinical studies have linked 
supplementation with fatty acids and probiotics, and anti-
inflammatory diets with improved symptoms and activities 
of daily living in patients with RA [85]. One case–control 
study in patients with RA showed that oral administration 
of creatine improves muscle mass, but no effect on muscle 
strength or function was observed [86]. The integrated man-
agement of IMRDs should include prevention, identification, 
and management of nutritional disorders [84].
Hugo et al. [87] performed an observational study to 
evaluate energy expenditure and nutritional complications 
in RA patients with metabolic syndrome and rheumatoid 
cachexia. They found that low levels of physical activity 
and GC use are associated with nutritional complications in 
patients with RA, suggesting a potential strategy for thera-
peutic intervention.
Conclusions and future research directions
The link between sarcopenia and rheumatoid diseases is an 
interesting growing area of study; however, it requires more 
in-deep studies (Table 1). To better understand the interac-
tion between these two groups of diseases and its potential 
treatment, geriatricians and rheumatologists need to work 
closely. Finally, it would be helpful to use modern defini-
tions of sarcopenia, and not just muscle mass definition, to 
get comparable and universal results.
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